IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Core Insights - IGC Pharma, Inc. announced preclinical findings on TGR-63, an investigational small-molecule candidate for Alzheimer's disease [1] - The data indicates that TGR-63 not only affects beta-amyloid pathology but also inhibits tau protein aggregation, which is another significant hallmark of Alzheimer's [1]